ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,301.13
1.21%
Dow Jones
43,221.55
1.65%
Gold vs US Dollar
2,692.315
0.89%
Brent Oil
81.445
-0.29%
Bitcoin
99,777.88
-0.74%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Syndax Pharmaceuticals Inc (SNDX)

  7. Syndax Pharmaceuticals Inc (SNDX) News

Syndax Pharmaceuticals (SNDX)

Syndax Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SNDX
DateTimeSourceHeadlineSymbolCompany
15/01/202522:34PR Newswire (US)Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial SizesNASDAQ:SNDXSyndax Pharmaceuticals Inc
13/01/202512:00PR Newswire (US)Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:SNDXSyndax Pharmaceuticals Inc
08/01/202502:20PR Newswire (US)Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law FirmNASDAQ:SNDXSyndax Pharmaceuticals Inc
07/01/202512:00PR Newswire (US)Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:SNDXSyndax Pharmaceuticals Inc
03/01/202521:05PR Newswire (US)Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:SNDXSyndax Pharmaceuticals Inc
20/12/202422:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNDXSyndax Pharmaceuticals Inc
09/12/202412:30PR Newswire (US)Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination TrialNASDAQ:SNDXSyndax Pharmaceuticals Inc
07/12/202423:15PR Newswire (US)Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual MeetingNASDAQ:SNDXSyndax Pharmaceuticals Inc
06/12/202421:28Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:SNDXSyndax Pharmaceuticals Inc
03/12/202421:05PR Newswire (US)Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:SNDXSyndax Pharmaceuticals Inc
27/11/202412:00PR Newswire (US)Syndax Announces Participation at the Citi 2024 Global Healthcare ConferenceNASDAQ:SNDXSyndax Pharmaceuticals Inc
15/11/202422:29PR Newswire (US)Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A TranslocationNASDAQ:SNDXSyndax Pharmaceuticals Inc
12/11/202412:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNDXSyndax Pharmaceuticals Inc
12/11/202412:00PR Newswire (US)Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of RevumenibNASDAQ:SNDXSyndax Pharmaceuticals Inc
05/11/202421:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SNDXSyndax Pharmaceuticals Inc
05/11/202421:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNDXSyndax Pharmaceuticals Inc
05/11/202421:01PR Newswire (US)Syndax Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:SNDXSyndax Pharmaceuticals Inc
05/11/202414:01PR Newswire (US)Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024NASDAQ:SNDXSyndax Pharmaceuticals Inc
05/11/202414:00PR Newswire (US)Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual MeetingNASDAQ:SNDXSyndax Pharmaceuticals Inc
05/11/202414:00PR Newswire (US)Syndax Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual MeetingNASDAQ:SNDXSyndax Pharmaceuticals Inc
04/11/202421:01PR Newswire (US)Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™NASDAQ:SNDXSyndax Pharmaceuticals Inc
01/11/202420:05PR Newswire (US)Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:SNDXSyndax Pharmaceuticals Inc
01/11/202411:00PR Newswire (US)Syndax Announces Participation in November Investor ConferencesNASDAQ:SNDXSyndax Pharmaceuticals Inc
29/10/202411:00PR Newswire (US)Syndax to Announce Third Quarter 2024 Financial Results and Host Conference Call and Webcast on November 5, 2024NASDAQ:SNDXSyndax Pharmaceuticals Inc
21/10/202420:11Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:SNDXSyndax Pharmaceuticals Inc
04/10/202420:05PR Newswire (US)Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:SNDXSyndax Pharmaceuticals Inc
18/09/202421:15PR Newswire (US)Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host DiseaseNASDAQ:SNDXSyndax Pharmaceuticals Inc
06/09/202420:05PR Newswire (US)Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:SNDXSyndax Pharmaceuticals Inc
15/08/202420:15Business WireIncyte und Syndax melden FDA-Zulassung von Niktimvo™ (Axatilimab-csfr) zur Behandlung der chronischen Graft-versus-Host-Krankheit (GvHD)NASDAQ:SNDXSyndax Pharmaceuticals Inc
15/08/202410:26Business WireIncyte et Syndax annoncent l’approbation par la FDA américaine de Niktimvo™ (axatilimab-csfr) pour le traitement de la maladie chronique du greffon contre l’hôte (GVHD)NASDAQ:SNDXSyndax Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:SNDX

Your Recent History

LSE
PIER
Brighton Pier
LSE
RRR
Red Rock Resources
LSE
GKP
Gulf Keystone Petroleum
LSE
ONT
Oxford Nanopore Technolo...
LSE
GLEN
Glencore
LSE
ALGW
Alpha Growth
LSE
SNG
Synairgen
LSE
PRTC
Puretech Health
LSE
OCDO
Ocado
LSE
STX
Shield Therapeutics
LSE
ZED
Zenova
NASDAQ
SLN
Silence Therapeutics
LSE
MNL
Manchester & London Inve...
LSE
SYME
Supply@me Capital
LSE
TPL
Tethys
LSE
GWMO
Great Western Mining
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2025 ADVFN PLC - All Rights Reserved

    Go Ad-Free

    Subscribe to Ad free and enjoy an ad-free experience

    No Ads

    Try Now

    Keep the Ads